Gilead

Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer.

Gilead's Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including breast, bladder and non-small cell lung cancers. Trodelvy is currently being investigated for use in combination with pembrolizumab as a first line treatment for PD-L1-high metastatic non-small cell lung cancer (mNSCLC) in the Phase 3 EVOKE-03 study. The efficacy and safety of Trodelvy in lung cancer has not been established.

Launch Therapeutics and Gilead have entered into a clinical collaboration agreement that establishes a Joint Steering Committee throughout the development of Trodelvy in mNSCLC.